Long-term effectiveness and safety of pravastatin in patients with coronary heart disease

Circulation

Volumn 133, Issue 19, 2016, Pages 1851-1860

  Hague, Wendy E ^a   Simes, John ^a   Kirby, Adrienne ^a   Keech, Anthony C ^a   White, Harvey D ^b   Hunt, David ^c   Nestel, Paul J ^d   Colquhoun, David M ^e   Pater, Helen ^a   Stewart, Ralph A ^b   Sullivan, David R ^f   Thompson, Peter L ^g   West, Malcolm ^h   Glasziou, Paul P ⁱ   Tonkin, Andrew M ^j  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e GREENSLOPES PRIVATE HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ BOND UNIVERSITY   (Australia)

^j MONASH UNIVERSITY   (Australia)

more..

Author keywords

cardiovascular diseases; cholesterol; coronary disease; hydroxymethylglutaryl CoA reductase inhibitors; lipids

Indexed keywords

ATORVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; OPEN STUDY; PATIENT SAFETY; PRIORITY JOURNAL; THERAPY EFFECT; CORONARY ARTERY DISEASE; LONGITUDINAL STUDY; MORTALITY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TIME FACTOR; TRENDS;

CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MULTICENTER STUDIES AS TOPIC; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TIME FACTORS;

EID: 84962130152     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018580     Document Type: Article

References (32)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 1301 1307
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335 1001 1009. doi: 10.1056/NEJM199610033351401
3. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 7 22
4. LIPID Study Group Tonkin A, Simes RJ, LIPID Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 1347 1357 LIPID Study Group
5. Law MR, Thompson SG, Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 1991 2 253 261
6. Davey Smith G, Pekkanen J, Should there be a moratorium on the use of cholesterol lowering drugs?. BMJ 1992 304 431 434
7. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G, Statins and the risk of colorectal cancer. N Engl J Med 2005 352 2184 2192. doi: 10.1056/NEJMoa043792
8. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE, Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005 162 318 325. doi: 10.1093/aje/kwi203
9. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, ASCOT Investigators The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J 2011 32 2525 2532. doi: 10.1093/eurheartj/ehr333
10. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-Analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 1267 1278. doi:10.1016/S0140-6736(05)67394-1
11. LIPID Study Group Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002 359 1379 1387. doi: 10.1056/NEJM199811053391902
12. Magliano D, Liew D, Pater H, Kirby A, Hunt D, Simes J, Sundararajan V, Tonkin A, Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. Aust N Z J Public Health 2003 27 649 653
13. Grambsch PM, Therneau TM, Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994 81 515 526
14. Deeks JJ, Altman DG, Bradburn MJ, Egger M, Davey Smith GD, Altman DG, Statistical methods for examining heterogeneity and combining results from several studies in meta-Analysis. In: Systematic Reviews in Health Care: Meta-Analysis in Context 2001 2nd ed London BMJ Publication Group
15. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A, Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001 38 56 63. doi: 10.1016/S0735-1097(01)01360-2
16. Heart Protection Study Collaborative Group Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R, Heart Protection Study Collaborative Group Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011 378 2013 20 Heart Protection Study Collaborative Group
17. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J, 4S Group Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004 364 771 777. doi: 10.1016/S0140-6736(04)16936-5
18. Ford I, Murray HM, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007 357 1477 1486
19. Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, Briggs A, Marchbank L, Comber H, Jukema JW, Westendorp RG, Trompet S, Buckley BM, Ford I, Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One 2013 8 e72642. doi: 10.1371/journal.pone.0072642
20. Simons LA, Ortiz M, Calcino G, Long term persistence with statin therapy-experience in Australia 2006-2010. Aust Fam Physician 2011 40 319 322
21. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J, Long-term persistence in use of statin therapy in elderly patients. JAMA 2002 288 455 461
22. Packard CJ, Ford I, Murray H, McCowan C, Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year followup of the West of Scotland Coronary Prevention Study American Heart Association Scientific Sessions Late-Breaking Clinical Trials; 7-11 Nov 2014; Orlando. Circulation 2014 130 2105 2126
23. Chang CC, Ho SC, Chiu HF, Yang CY, Statins increase the risk of prostate cancer: a population-based case-control study. Prostate 2011 71 1818 1824. doi: 10.1002/pros.21401
24. Bardou M, Barkun A, Martel M, Effect of statin therapy on colorectal cancer. Gut 2010 59 1572 1585. doi: 10.1136/gut.2009.190900
25. Lutski M, Shalev V, Porath A, Chodick G, Continuation with statin therapy and the risk of primary cancer: a population-based study. Prev Chronic Dis 2012 9 E137. doi: 10.5888/pcd9.120005
26. Alberton M, Wu P, Druyts E, Briel M, Mills EJ, Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-Analysis. QJM 2012 105 145 157. doi: 10.1093/qjmed/hcr158
27. Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, Clopton P, DeMaria AN, Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011 58 530 537. doi: 10.1016/j.jacc.2011.04.015
28. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J, Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010 126 279 284. doi: 10.1002/ijc.24536
29. CTT Collaboration Lack of effect of lowering LDL cholesterol on cancer: meta-Analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012 7 e29849
30. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 360 1623 1630
31. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A, Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001 134 931 940. doi: 10.7326/0003-4819-134-10-200105150-00007
32. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R, Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008 359 1357 1366. doi: 10.1056/NEJMsa0806603